Kiran Mazumdar Shaw, CMD, Biocon, calls this to be an irrational commentary from the government‘s side, as it will only the end-user—the patient—who will have to pay the increased cost.
first published: Feb 5, 2016 08:55 pm
A collection of the most-viewed Moneycontrol videos.

Nifty Clocks Second Week Of Gains But Still Awaits New Peak;Midcaps Snap 7-Week Run|Closing Bell

Will Nifty Bulls March Towards Fresh Peak Despite Dismal Global Cues? | Opening Bell Live

Nifty Aims For Next 26,100 After Hitting 3-Week High |Opening Bell Live

Nifty Back Above 26,000 As IT Stocks Sprint Ahead; Nvidia Earnings In Focus| Closing Bell Live
You are already a Moneycontrol Pro user.

